http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 11 Mar 2026 17:41:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+09++Filed+by%3A+Khan+Najat/26147385.html si-local-file:///var/storage/secattach/20260311/26147385.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+09++Filed+by%3A+Khan+Najat/26147385.html Wed, 11 Mar 2026 17:41:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+09++Filed+by%3A+Khan+Najat/26147385.html si-local-file:///var/storage/secattach/20260311/26147385.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+09++Filed+by%3A+Khan+Najat/26147385.html Wed, 11 Mar 2026 17:41:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+09++Filed+by%3A+Gibson+Christopher/26147387.html si-local-file:///var/storage/secattach/20260311/26147387.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+09++Filed+by%3A+Gibson+Christopher/26147387.html Wed, 11 Mar 2026 17:41:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+09++Filed+by%3A+Gibson+Christopher/26147387.html si-local-file:///var/storage/secattach/20260311/26147387.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+09++Filed+by%3A+Gibson+Christopher/26147387.html Wed, 11 Mar 2026 17:41:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Khan+Najat/26131184.html si-local-file:///var/storage/secattach/20260309/26131184.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Khan+Najat/26131184.html Mon, 09 Mar 2026 13:45:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Khan+Najat/26131184.html si-local-file:///var/storage/secattach/20260309/26131184.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Khan+Najat/26131184.html Mon, 09 Mar 2026 13:45:00 -0400 O.34383149 RXRX http://www.streetinsider.com/Board+Changes/PacBio+adds+Recursion+co-founder+Chris+Gibson+to+board/26115728.html <p>PacBio (NASDAQ: PACB) announced the appointment of Christopher Gibson to its board of directors. Gibson co-founded and serves as chairman of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company focused on AI-driven drug discovery.</p> <p>Gibson led Recursion from inception through capital formation, strategic partnerships and a public listing. The company developed a platform that generates and analyzes biological datasets spanning drug discovery, clinical data and electronic health records to train machine learning models for drug development.</p> <p>"Dr. Gibson has demonstrated how AI, automation, and high-dimensional biological data can be combined to transform scientific discovery," said Christian Henry, PacBio's chief executive officer. "As HiFi http://www.streetinsider.com/Board+Changes/PacBio+adds+Recursion+co-founder+Chris+Gibson+to+board/26115728.html Thu, 05 Mar 2026 08:31:12 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Board+Changes/PacBio+adds+Recursion+co-founder+Chris+Gibson+to+board/26115728.html <p>PacBio (NASDAQ: PACB) announced the appointment of Christopher Gibson to its board of directors. Gibson co-founded and serves as chairman of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company focused on AI-driven drug discovery.</p> <p>Gibson led Recursion from inception through capital formation, strategic partnerships and a public listing. The company developed a platform that generates and analyzes biological datasets spanning drug discovery, clinical data and electronic health records to train machine learning models for drug development.</p> <p>"Dr. Gibson has demonstrated how AI, automation, and high-dimensional biological data can be combined to transform scientific discovery," said Christian Henry, PacBio's chief executive officer. "As HiFi http://www.streetinsider.com/Board+Changes/PacBio+adds+Recursion+co-founder+Chris+Gibson+to+board/26115728.html Thu, 05 Mar 2026 08:31:12 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Board+Changes/PacBio+adds+Recursion+co-founder+Chris+Gibson+to+board/26115728.html <p>PacBio (NASDAQ: PACB) announced the appointment of Christopher Gibson to its board of directors. Gibson co-founded and serves as chairman of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company focused on AI-driven drug discovery.</p> <p>Gibson led Recursion from inception through capital formation, strategic partnerships and a public listing. The company developed a platform that generates and analyzes biological datasets spanning drug discovery, clinical data and electronic health records to train machine learning models for drug development.</p> <p>"Dr. Gibson has demonstrated how AI, automation, and high-dimensional biological data can be combined to transform scientific discovery," said Christian Henry, PacBio's chief executive officer. "As HiFi http://www.streetinsider.com/Board+Changes/PacBio+adds+Recursion+co-founder+Chris+Gibson+to+board/26115728.html Thu, 05 Mar 2026 08:31:12 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Board+Changes/PacBio+adds+Recursion+co-founder+Chris+Gibson+to+board/26115728.html <p>PacBio (NASDAQ: PACB) announced the appointment of Christopher Gibson to its board of directors. Gibson co-founded and serves as chairman of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company focused on AI-driven drug discovery.</p> <p>Gibson led Recursion from inception through capital formation, strategic partnerships and a public listing. The company developed a platform that generates and analyzes biological datasets spanning drug discovery, clinical data and electronic health records to train machine learning models for drug development.</p> <p>"Dr. Gibson has demonstrated how AI, automation, and high-dimensional biological data can be combined to transform scientific discovery," said Christian Henry, PacBio's chief executive officer. "As HiFi http://www.streetinsider.com/Board+Changes/PacBio+adds+Recursion+co-founder+Chris+Gibson+to+board/26115728.html Thu, 05 Mar 2026 08:31:12 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Press+Releases/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html <p>MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors.</p> <p>Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company that has built one of the industry’s most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional biology, and artificial intelligence. He http://www.streetinsider.com/Press+Releases/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html Thu, 05 Mar 2026 08:30:00 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Press+Releases/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html <p>MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors.</p> <p>Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company that has built one of the industry’s most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional biology, and artificial intelligence. He http://www.streetinsider.com/Press+Releases/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html Thu, 05 Mar 2026 08:30:00 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Press+Releases/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html <p>MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors.</p> <p>Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company that has built one of the industry’s most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional biology, and artificial intelligence. He http://www.streetinsider.com/Press+Releases/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html Thu, 05 Mar 2026 08:30:00 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Press+Releases/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html <p>MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors.</p> <p>Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company that has built one of the industry’s most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional biology, and artificial intelligence. He http://www.streetinsider.com/Press+Releases/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html Thu, 05 Mar 2026 08:30:00 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Globe+Newswire/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html <p>MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors.</p> <p>Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company that has built one of the industry’s most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional biology, and artificial intelligence. He http://www.streetinsider.com/Globe+Newswire/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html Thu, 05 Mar 2026 08:30:00 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Globe+Newswire/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html <p>MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors.</p> <p>Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company that has built one of the industry’s most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional biology, and artificial intelligence. He http://www.streetinsider.com/Globe+Newswire/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html Thu, 05 Mar 2026 08:30:00 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Globe+Newswire/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html <p>MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors.</p> <p>Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company that has built one of the industry’s most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional biology, and artificial intelligence. He http://www.streetinsider.com/Globe+Newswire/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html Thu, 05 Mar 2026 08:30:00 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/Globe+Newswire/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html <p>MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors.</p> <p>Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company that has built one of the industry’s most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional biology, and artificial intelligence. He http://www.streetinsider.com/Globe+Newswire/PacBio+Announces+the+Appointment+of+Chris+Gibson+to+the+Board+of+Directors/26115703.html Thu, 05 Mar 2026 08:30:00 -0400 O.01128999 O.34383149 PACB RXRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+03++Filed+by%3A+Borgeson+Blake/26112002.html si-local-file:///var/storage/secattach/20260304/26112002.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+03++Filed+by%3A+Borgeson+Blake/26112002.html Wed, 04 Mar 2026 16:39:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+03++Filed+by%3A+Borgeson+Blake/26112002.html si-local-file:///var/storage/secattach/20260304/26112002.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Mar+03++Filed+by%3A+Borgeson+Blake/26112002.html Wed, 04 Mar 2026 16:39:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Borgeson+Blake/26099495.html si-local-file:///var/storage/secattach/20260303/26099495.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Borgeson+Blake/26099495.html Tue, 03 Mar 2026 12:45:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Borgeson+Blake/26099495.html si-local-file:///var/storage/secattach/20260303/26099495.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Borgeson+Blake/26099495.html Tue, 03 Mar 2026 12:45:00 -0400 O.34383149 RXRX http://www.streetinsider.com/Analyst+PT+Change/Recursion+Pharmaceuticals+%28RXRX%29+PT+Lowered+to+%246+at+BofA+Securities/26058003.html <p>BofA Securities analyst Derik de Bruin lowered the price target on Recursion Pharmaceuticals (NASDAQ: RXRX) to $6.00 (from $7.00) while maintaining a Neutral rating.</p><p>The analyst comments "Our thesis remains that, for meaningful rerating, Recursion needs repeatable clinical wins that show the OS can translate AI-derived biology into differentiated molecules and patient-relevant outcomes. We think FAP data for REC-4881 (see our 8 December 2025 report) is a solid start, though most clinical value unlocks appear more of a 2027e story. Cash burn discipline/partnership progress remain positive components, but we see pipeline readouts as key to gain more credence in the name. http://www.streetinsider.com/Analyst+PT+Change/Recursion+Pharmaceuticals+%28RXRX%29+PT+Lowered+to+%246+at+BofA+Securities/26058003.html Wed, 25 Feb 2026 12:03:14 -0400 RXRX http://www.streetinsider.com/Analyst+Comments/Recursion+Pharmaceuticals+%28RXRX%29+PT+Lowered+to+%246+at+BofA+Securities/26058003.html <p>BofA Securities analyst Derik de Bruin lowered the price target on Recursion Pharmaceuticals (NASDAQ: RXRX) to $6.00 (from $7.00) while maintaining a Neutral rating.</p><p>The analyst comments "Our thesis remains that, for meaningful rerating, Recursion needs repeatable clinical wins that show the OS can translate AI-derived biology into differentiated molecules and patient-relevant outcomes. We think FAP data for REC-4881 (see our 8 December 2025 report) is a solid start, though most clinical value unlocks appear more of a 2027e story. Cash burn discipline/partnership progress remain positive components, but we see pipeline readouts as key to gain more credence in the name. http://www.streetinsider.com/Analyst+Comments/Recursion+Pharmaceuticals+%28RXRX%29+PT+Lowered+to+%246+at+BofA+Securities/26058003.html Wed, 25 Feb 2026 12:03:14 -0400 RXRX http://www.streetinsider.com/Press+Releases/AI+Biotech%2C+APAC+Expansion%2C+and+Balance+Sheet+Rebuilds+Set+the+Morning+Tone/26056689.html <p>DENVER, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a strong crosscurrent of AI-powered drug discovery, cross-border biologics distribution, and capital structure resets. From micro-cap transformation stories to cash-rich TechBio platforms, this morning’s tape highlights companies positioning for scale in 2026 and beyond.</p> <p><strong>Totaligent Targets APAC Biologics and Medical Tourism</strong></p> <p>Totaligent (OTCID: TGNT) announced the execution of a <strong>binding Letter of Intent (LOI)</strong> with GloMed Solutions Limited Liability Company, a Japanese medical aesthetics and biologics distributor, to form a joint venture integrating Totaligent’s recently announced Aetherium Medical platform.</p> <p>The agreement establishes a JV http://www.streetinsider.com/Press+Releases/AI+Biotech%2C+APAC+Expansion%2C+and+Balance+Sheet+Rebuilds+Set+the+Morning+Tone/26056689.html Wed, 25 Feb 2026 09:38:05 -0400 NXPL RXRX XWEL